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Abstract
In this paper we introduce The Drugulator - a new method for performing dosage calculations at
the administration stage of a patient's medical management. In this method users first construct a
dosage's mathematical formulation from within the Drugulator's structured interface. This formula-
tion is then evaluated by sending it to an attached computational backend that then returns any
constituent calculations along with the patient's final dose. This process of Formulaic and Compu-
tationally-Aided Dosing (FCAD), and in particular, the single-interface Drugulator implementation
described here, makes it practical to readily automate a wide range of dosage calculations at the
point of care. This practicality also enables further automation through a progressive integration
with existing medical systems. Finally, we argue that the principle underpinning the deployment of
a single interface can also be used to improve the usability of those computer provider order entry
systems that include clinical decision support (CPOEcds).
Keywords: Drug dosage calculations, medication errors, educational technology, 
algorithms, automation, systems integration
1. Introduction
The main purpose of this paper is to
present the Drugulator as a viable
clinical tool for calculating drug dos-
ages at the administration stage of the
medication process. To this end, its
basic operation and underlying princi-
ple will be described, illustrated and
discussed with several examples.
There is also an initial web imple-
mentation[1] where these descrip-
tions can be experienced first-hand
and a wider range of examples con-
sulted from the accompanying user
manual. A more general goal of the
paper is to highlight the need for more
research into the application of
FCADs at this stage of the adminis-
tration process and how they can be
integrated with medical systems that
automate other stages. As part of this,
several metrics are developed as a
way to initially evaluate FCADs (and
are applied to the Drugulator), while
the Drugulator's underlying Con-
structor principle is developed and
used to show how such systems can
be both applied to, and connected
with, CPOEs.
1.1. Rationale
The most significant and immediate
application of FCADs like the Drugu-
lator is as the calculating component
of a system designed to address the
current, unacceptably high levels of
Adverse Drug Events (ADEs) in hos-
pital systems. This need follows from
the by now well-documented analyses
of the casualties and associated costs -
we quote again some of the more
sobering statistics: In the US, it is
estimated that in a large 700 bed hos-
pital, medical errors cost $5.6 mil-
lion[2] annually while over a decade
ago the total cost of drug-related
errors in the US alone was put at 76
billion[3]. On the human side, it has
been estimated that ADEs make up
19%[4] of the general medical errors
that are responsible for between
44000 & 98000 deaths a year - a
higher mortality rate than that of car
accidents, suicide, homicide or
AIDS[5]. Finally, there is evidence
that if you enter a hospital as a
patient, there is a 6.5-11% chance that
any proffered medicine will increase
your hospital stay by an additional 2.2
days or a 0.065% chance the accepted
medication will contribute to your
death[2, 6-9].
The process through which ADEs
occur is clearly multi-faceted but one
framework designed to pinpoint criti-
cal junctures is a medical manage-
ment model that describes 5 stages -
Prescribe->Transmit->Dispense-
>Administer->Monitor[10]. Of these
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stages, there is consistent evidence
that the most significant stages in
terms of ADEs' root causes are the
Prescribe and Administer stages[10].
For example, the Prescribe stage has
been variously estimated as being
responsible for: 39%[8], 43%[11],
56%[7], 58%[12], 59%[8], 61%[13],
79%[14], percent of ADEs while the
Administer stage has been variously
estimated as contributing to such
events:  4%[14], 13%[13], 21%[12],
34%[7], 38%[8], 44%[15], 52%[11],
57%[8] of the time. In this paper, we
focus on the Administer stage and, in
particular, the calculating component
used to generate a correct dosage
within a FCAD. 
Failure to reach the correct dosage
has been variously identified as con-
tributing to 36%[16], 58%[10],
60%[17], 67%[15] of the errors in the
Administer stage with the calculation
process a central component in this
failure. While we focus on the calcu-
lating component of the Administer
stage and hence the way in which the
Drugulator can assist nurses in such
calculations, the underlying principle
used by the Drugulator also has rele-
vance to the Prescribe stage. Indeed,
it will be argued that applying this
principle to simplify the interfaces of
CPOE systems is a way to maintain a
certain level of usability in the face of
increasingly complex prescriptions
that incorporate larger numbers of
variables.
The main way in which it is envi-
sioned that the Drugulator can reduce
ADEs is through health-care workers
using its single machine interface to
perform all their dosage calculations
in a more efficient, accurate and ulti-
mately safer manner. The words sin-
gle and all have been emphasized
here since we argue that they repre-
sent the Drugulator's key advantage
over both traditional pen/paper/calcu-
lator methods and the suite of existing
dosage calculators. The advantage of
this single interface is that it over-
comes serious usability issues arising
from the use of multi-interface
arrangements in current systems.
Here and for the remainder of the
paper “Single Interface” should be
interpreted as short-hand for suffi-
ciently usable Single Interface. This
qualification is necessary because a
collection of different interfaces can
always be combined into a single but
now more complex interface. While
this results in a single interface (that
contains all the possible calculations
previously contained in the different
interfaces), the trade-off is a loss of
usability given that users now have to
negotiate within a screen of far
greater complexity. This trade-off in
usability is made more precise later in
the Efficiency Index section in which
the Drugulator advantage can be seen
by the way in which it minimizes the
number of persisting fields while at
the same time maximizing the
number of calculations that can be
performed using such fields.
A central component of this usabil-
ity relates to the efficiency associated
with the average time needed to per-
form a dosage calculation. In CPOE
systems (for which more research has
been conducted) this time factor has
been identified as critical. For exam-
ple, in one review the first of Ten
Commandments to implementing
effective CPOEs is Speed is Every-
thing[18] and this exhortation has
continually informed best prac-
tice[19] and the generation of Order
Sets[20]. Further, its lack has been
identified as a key barrier to the
adoption of hand-held medical
devices[21]. While this impetus has
been researched mostly for the Pre-
scribe stage, there is emerging evi-
dence that nurses in the Administer
stage face similar time pressures[16,
22] that can, to some extent be
addressed by the introduction of
FCADs.
Another application for the Drugu-
lator is in the education and training
of health-care professionals involved
in point of care drug administration.
This includes those who will not nec-
essarily be accessing the Drugulator
as part of their clinical practice but
who can nonetheless benefit from
using its interface as part of their
training in traditional pen/paper/cal-
culator procedures. In particular, by
mastering the Drugulator's operation,
apart from being able to check
answers arrived at in the traditional
way, learners are able to gain an
insight into the single principle that
underpins a wide range of calcula-
tions. Finally, the other more long-
term application for the Drugulator is
that its method, through its interface
design, provides opportunities for
ongoing reductions in ADE occur-
rences via a pathway leading to a fur-
ther automation of point of care drug-
delivery. This pathway involves the
integration of existing and emerging
hospital systems by leveraging a cer-
tain extensibility that is inherent to
the method and is explained later in
the section A Developmental Blue-
print.
1.2. Comparison with 
Existing Methods
Calculating a patient's dose at the
Administer stage can be done in vari-
ous ways and the following is a rough
categorization of the existing meth-
ods: 1) Inspection 2) Pen/Paper 3)
Pen/Paper/Calculator and 4) Compu-
ter/PDA. Method 1 involves a dosage
calculation being performed in a
user's head and is therefore usually
appropriate for straightforward tablet
calculations. Method 2 involves users
constructing the complete mathemati-
cal expression before evaluating it by
carrying out the consequent arithmet-
ical manipulations on paper. Method
3 is essentially Method 2 except that a
calculator is used to evaluate the con-
structed expression. Method 4
includes a range of computational
tools/dosage calculators that have
emerged over the last decade. These
range from freely available online
calculators[23] to commercially
released systems[24] that form part of
more generalized health care tools.
The actual uptake of these tools in the
Administer stage however, has not
been as pervasive due, as we will
argue, to a specific usability issue
related to a FCAD's efficiency.
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Method 3 has been by far and away
the most common of all the methods
over the past 50 years with various
curriculum programs and clinical pro-
cedures instituted as befitting such a
long-standing practice. Despite these
programs however, the remaining
high ADE levels, or at least those
attributable to drug calculation error,
constitute persuasive evidence of
these programs' inherent limitations
and suggest the need for a new
approach. In this paper we take the
position that the additional layers of
automation and checking possible in
Method 4, if feasible in the clinical
situation, will ultimately represent an
improvement (in a similar  way
CPOEcds are beginning to improve
the Prescribe stage) but acknowledge
that further studies will be needed as
confirmation. Hence, any compari-
sons of the Drugulator for the remain-
der of this paper will be less with the
status-quo of Method 3 and more with
the interface design of existing dos-
age systems within Method 4. 
As mentioned previously, the fun-
damental difference between the Dru-
gulator and existing dosage
calculators is its use of a single inter-
face. The most important and imme-
diate effect of this single interface
approach is in establishing the feasi-
bility of automating point-of-care
dosage calculation in a general way.
That is, the current approach of
searching amongst a large number of
interfaces (each corresponding to a
possible dosage calculation) is funda-
mentally limited by the average time
such a process takes. The point of the
Drugulator is that such a search
becomes unnecessary since the
required dosage calculations can be
conducted from its single interface at
the point of care.
There are other less fundamental
differences between the Drugulator
and other systems (e.g. features that
are transferable between the various
interfaces) but that can nonetheless
affect their usability and therefore
their general ability to reduce ADEs.
These differences include such fea-
tures as dosage output form, internal
transparency, pharmacopoeia integra-
tion, server-side architecture, compu-
tational engine, general workflow etc.
Some of these features are introduced
for the first time in the Drugulator
whilst some other features from more
established systems could no doubt
improve the Drugulator's overall
effectiveness. These comparisons are
discussed in turn as they are intro-
duced as part of the Drugulator archi-
tectural description in the System
Description section and in the Appen-
dix.
2. System Description
2.1. Status Report
The Drugulator was conceived by
the author while working in the Port-
folio of Language and Learning at
Victoria University (VU). This port-
folio targets learning support in prob-
lematic areas identified by the
University’s faculties and schools. In
2005, The School of Nursing and
Midwifery requested support for its
nursing cohort of ~800 students in
relation to their dosage calculations.
A Drugulator prototype was pre-
sented to the faculty firstly as a means
for students to generate the correct
answer (to check their competence
using traditional pen/paper/calculator
methods) but also as a way for stu-
dents to recognize a common princi-
ple underpinning all their
calculations. With the prototype
approved, there followed a period of
development and refinement using
feedback from faculty staff, local
website design companies and stu-
dents. In early 2007, a developer was
hired to measure server performance
and develop tools to monitor real-
time student usage of the system. In
the second semester of 2007 the site
and interface was released to VU's
nursing cohort.
It was recognized fairly early on
that apart from this pedagogical appli-
cation, allowing users to more effi-
ciently and accurately calculate drug
dosages has clinical benefits if it was
readily available in the clinical envi-
ronment. A business case study was
then commissioned by VU to com-
pare cost savings from potential ADE
reductions with the cost of developing
a customized hand-held product. As
of early 2009 the University is seek-
ing partners as part of the final round
of IP protection[25].
The Drugulator is designed to be
used by any health-care professional
needing an efficient tool to compute
patient drug dosages. At the point of
care, such a tool would therefore cur-
rently be most useful for practicing
nurses. Away from the point of care
and, in particular, where users require
dosage calculations involving a large
number of variables, physicians,
pharmacists, drug researchers can
usefully apply the system to systemat-
ically automate a wide range of drug
calculations. Students in any of the
aforementioned areas would also ben-
efit from learning to operate the Dru-
gulator given that such operation
requires and demonstrates an under-
standing of a common principle
underpinning a wide variety of possi-
ble dosage calculations.
2.2. Overview & Illustration
In this initial description it is
intended to convey the standard
work-flow and a sense of the underly-
ing Constructor principle that forms
the basis of the Drugulator operation.
Such a sense should be sufficient for
our later discussion of the Drugulator
method in relation to general FCAD
and CPOE interfaces. For complete
details however, of both the mathe-
matical manipulations and the roles
played by each of the interfaces’ com-
ponents, readers should consult the
Appendix. Note that the Appendix
also contains a range of worked
examples as part of demonstrating the
interface’s claimed versatility.
Finally, an even more comprehensive
list of the dosage calculations that are
possible using this principle can be
found within the online Drugulator
resource[1].
The Drugulator interface is shown
in Figure 1 and consists of two sepa-
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rate interfaces. The left-hand side
(L.H.S.) interface is used for any pre-
liminary stock concentration calcula-
tions. It operates on more or less the
same principle as the right-hand side
(R.H.S.) interface which is the inter-
face that ultimately computes the
patient’s dose, and hence the interface
on which we shall focus.
                                    Figure 1: The Drugulator Interface before starting a drug calculation
The basic idea behind the interface
is that users effectively construct a
mathematical expression correspond-
ing to the required dose by identifying
three main components of a dose’s
calculation. The first component is
simply those variables involved in the
dose - with one variable distinguished
as that corresponding to the required
amount. The second component to be
identified is the “base dose” that has
been ordered for the patient’s condi-
tion. The third component relates to
how this base dose is modified
according to the particular patient.
Once these three components have
been expressed in the interface, click-
ing the “=” button generates the con-
structed expression along with its
evaluation corresponding to the final
dose amount. 
In Figure 2 therefore, the three
components to be identified in
calculating the correct dose (from
information in the top Dose
Description panel) are expressed in
the interface as follows:
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                               Figure 2: A weight-based calculation using the Drugulator’s  R.H.S. sub-interface.
The first component – identifying
the relevant variable – is expressed by
the colouring of the three rows; Drug
Weight, Time and Patient Weight with
the Drug Weight variable distin-
guished (with a red colouring given it
is this variable’s value that is being
sought). The second component, the
base dose, is a 40 mg/kg/day prescrip-
tion and is expressed in the first col-
umn – the Dose Ordered panel. The
final component, the information spe-
cific to this patient’s administration
appears in the second column - the
Dose Delivered panel. With these fea-
tures in place, clicking the “=” button
causes the constructed mathematical
expression to appear to the left of the
“=” sign along with the numerical
value it evaluates to, on the right hand
side of this “=” sign.
Currently in this interface the con-
structed expression reflects a propor-
tional relationship that is assumed to
exist between the dose variable and
the other variables on which it
depends (note also that any unit con-
versions are handled automatically).
Such a relationship, perhaps surpris-
ingly, includes the vast majority of
dosages required of nurses and hence
needed by any putative FCAD1. This
coverage is what gives the interface
its general utility and evidence for
this claim, as mentioned earlier, is
provided in the Appendix.
2.3. Performance Metrics
The main design objective of the
Drugulator to be discussed here
relates to its viability as a calculating
tool at the point of care. This viability
specifically relates to its efficiency
over a sufficiently wide range of
required dosage calculations.
Currently there does not appear to be
any standard measure of this viability
and indeed, one of the motivations of
this paper is to highlight the need for
more comprehensive studies into the
effectiveness of FCADs being
considered for clinical application.
To this end we introduce several
measures as a way of providing an
initial evaluation (with each
subsequently applied to the
Drugulator). Initial evaluations can
be a useful filter to identify unviable
systems but are clearly not sufficient
for any mooted clinical adoption. For
this, comprehensive, longitudinal
studies over a variety of situations
and with large numbers of users are
needed. Such trials have not been
carried out on the Drugulator
although in what follows we describe
several design features that, we argue,
provide natural advantages in relation
to the developed metrics.
2.3.1. A FCAD 
Categorization
The main performance metric(s)
will be framed around three different
FCAD categories - Selectors,
Constructors and Open-Enders (see
Figure 3). This categorization is
useful because it distinguishes
between current practice, existing
automated systems and the
Drugulator method. Each category
also defines qualitatively different
FCAD user-experiences which will
be reflected in different scores on the
defined metrics.
1. This fact greatly simplifies the underlying implementation although such a relationship is not an intrinsic feature of the method: For example, later 
we show how it can be extended to other variables/ relationships and hence as part of a comprehensive CPOEcds.
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                   Figure 3 : Categorizing a FCAD as either a- Selector, Constructor or Open-Ender
Selectors, the most common type of
dosage system, are categorized by
having a separate interface for each
possible dosage calculation. Con-
structors, of which the Drugulator is
an initial implementation, are distin-
guished by the way in which dosages
are constructed from the relevant
dose variables. Open-Enders incorpo-
rate the current method whereby
essentially any calculation can be per-
formed and hence, in particular, any
possible dosage calculation. We now
discuss three different metrics in rela-
tion to systems defined in each of
these categories.
2.3.2. Coverage
The coverage of any FCAD - the
range of possible calculations it is
able to perform - is a basic part of any
system’s evaluation and hence, we
argue, should be the first step in any
systematic analysis.  We frame the
analysis of coverage here around the
previous categorization but briefly
note the following: The coverage of
Selectors is finite (essentially equal to
the number of different interfaces in
the system) but, as we will illustrate,
is of an order of magnitude less than
the coverage of Constructors (which
is also finite). The coverage of Open-
Enders is infinite.
2.3.3. Open-Enders
In principle, the use of pen/paper/
calculator allows the health practi-
tioner to perform any possible dosage
calculation. While obviously useful,
such freedom also includes the free-
dom to commit any type of error. Fur-
thermore, dosage calculations contain
certain repetitive components through
which efficiencies can be gained by
collecting them into a computer inter-
face. Finally, there are other reasons
related to automated checking and
links to decision-support systems
that, when combined with persistently
high ADE rates, makes a compelling
case to consider ending this method
of dosage calculation in the clinical
setting. In most of what is to follow
we will be more concerned with com-
paring Selectors with Constructors.
2.3.4. Constructors
In Constructors users construct a
mathematical expression correspond-
ing to the required dosage calculation
by first "activating" those variables
involved in the calculation. Since
there can only ever be a finite number
of variables in the system at any one
time, the number of possible dosage
calculations that can be performed by
a constructor system is therefore also
finite1. The freedom however, of
being able to choose the relevant var-
iables - amongst say n different varia-
bles - means that an exponential number,
2n of different dosage calculations
becomes possible. Mathematically,
this is simply the size of the power set
of n elements but in the Drugulator
context can be observed by noting
that each row can either be in the "on"
or "off" position depending on
whether or not the corresponding var-
iable is activated. The total number of
ways each of n rows can be either
"on" or "off" is 2n.
While the freedom of choosing var-
iables allows any calculation using
such variables to be constructed, the
constraint associated with the way in
which the system forms the corre-
sponding mathematical expression,
means that there is less opportunity
for non-dosage computations to be
formed. Currently (as detailed in the
Appendix), the way in which the system
forms the corresponding mathematical
expression assumes a proportional
relationship between independent
variables and the final calculated dos-
age. It turns out this is sufficient for
the vast majority of point of care drug
calculations although this propor-
tional relationship, is not an inherent
feature of constructor method within
a FCAD. Indeed, other relationships
can be readily augmented with the
addition of new variables. 
The Drugulator method, as far as
we are aware, is the only dosage cal-
culator or FCAD that employs the
constructor method and we can, based
on the previous argument, use it to
estimate its coverage. There are two
interfaces to consider. Firstly, the
L.H.S. Stock Concentration interface
1. This finiteness refers to a “frozen” version or a particular FCAD instance. Any FCAD’s range can, of course, always be extended via its ongoing 
maturation (which for Constructors would mean the addition of new variables).
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has 2 different configurations depend-
ing on which of the two variables is
identified as being dependent
(thereby consigning the remaining
variable to be independent). Sec-
ondly, the R.H.S. interface specifies 4
variables giving 24 different ways
these can be activated. A preliminary
stock concentration is either required
or not giving a final coverage of
2×2×24 = 64. In practice, the actual
number of calculations will be some-
what less than this due to certain
administering constraints associated
with dosing practice in general (e.g.
the dependent variable is most likely
to be either Drug Weight or Drug Vol-
ume and both are unlikely to ever be
simultaneously activated). Hence, 64
is the maximum number of different
dosage calculations that involve pro-
portionate relationships between
dependent and independent variables
drawn from Drug Weight, Drug Vol-
ume, Time and Patient Weight
(including a possible preliminary
stock concentration calculation)1.
2.4. Selectors
The selector approach invariably
used by current dosage calculating
systems, involves setting up a sepa-
rate interface for a separate dosage
calculation. This interface can then be
used when the corresponding calcula-
tion is required. Hence the coverage
of such systems is equal to the
number of such interfaces so con-
structed - a value which invariably
reflects the system's maturity. The
selector approach is therefore poten-
tially useful when the total number of
different interfaces is low and the
interfaces contain a large number of
specific and unusual variables. Con-
versely, when common variables are
repeatedly combined to produce the
final dosage calculation, the system's
coverage becomes exponential in the
number of possible variables. That is,
n different variables give rise to 2n
possible dosage calculations which
then require, under a selector method,
2n different interfaces.
2.4.1. Comparing 
Coverages
In principle, both Constructors and
Selectors can be designed to cover the
same range of calculations. The fun-
damental difference between the two
methods however, becomes apparent
once their respective usability over
the entire range of possible dosage
calculations is considered2. This will
be reflected in the time taken to navi-
gate amongst this range but this time
can also be directly estimated with
another measure specifically related
to a system's coverage - namely its
Efficiency Index. Before defining this
measure, we motivate its definition
by recalling the most immediate man-
ifestation of employing a Constructor
or a Selector - namely the number of
resulting interfaces. Collectively
reviewing the examples in the Appen-
dix (or a more extended range from
its online manual) shows that many of
the Drugulator's input fields are being
repeatedly re-used. In effect, common
types of arguments are being
"extracted" from various functions
that each implement a different dos-
age calculation. This extraction
means that similar types of arguments
are not being repeated each time the
function and its corresponding dosage
needs to be calculated. For example,
Time is involved in every dosage cal-
culation that involves some sort of
rate. In the Drugulator's single inter-
face, instead of an input field corre-
sponding to Time being repeated for
every such calculation, it appears
only once and hence can be activated
from the one interface when required.
2.4.2. Efficiency Index
The aforementioned description
captures how "extracting common
arguments" can result in a single
interface and the associated usability
advantages. On the other hand, it
could be argued that any other dosage
system employing the selector
approach (i.e. with 1-interface per 1-
calculation), could in principle, also
employ a single interface simply by
concatenating all of its interfaces into
one "super-interface". Naturally such
a super-interface would have serious
usability issues both in terms of users
finding the appropriate "sub-inter-
face" (in effect, the aforementioned
search is now being conducted on a
single screen) as well as navigating
amongst all the necessarily com-
pressed input fields. The above two
examples motivate the following Effi-
ciency Index (EI) definition for
FCADs. The definition aims to meas-
ure and distinguish between, the effi-
ciency gained from re-using
arguments as in the constructor model
and the lack of efficiency in the 1-
interface 1-calculation paradigm
characterized by Selectors.
.
Hence, the Efficiency Index of a
FCAD system measures the number
of different calculations per input
field. In the Drugulator interface, for
example, there are 24 inputs (4 inputs
for each of the 6 rows that in total
make up the L.H.S. and R.H.S inter-
faces) so that a coverage of 64 gives
an EI (Drugulator) of (64/24) ~ 2.67.
For a Selector, employing a 1-inter-
face 1-calculation approach, the EI
reduces to the reciprocal of the aver-
age number of inputs per calculation.
Estimating this average at ~6 we have
an EI estimate of 1/6 = 0.2 for a
Selector (that is invariant to concate-
nation). Note that for arbitrary n, we
have EI(Constructor) ~ O(2n)
whereas EI(Selector)~1. Hence we
see that this index measures the effi-
ciency with which input fields are re-
used and is, as we will argue, ulti-
mately correlated with the time it
takes for users to perform a typical
dosage calculation - an issue to which
we now turn.
1. Note that implicit in discussions of the Drugulator's coverage is that dosage calculations differing only in the value of the respective inputs are still 
considered to be the same. For example, changing a quantity’s units is not counted as changing  the type of calculation.
2. One other significant difference is the ease of implementation between the two types of systems. Since a Constructor involves grouping variables 
that are related in similar ways, this relationship need only be implemented once. For example, activated variables in the Drugulator interface define 
a proportional relationship between variables and hence this proportionality, once implemented, can be used to cover a variety of situations.
EI Sys( ) Coverage Sys( )# Inputs---------------------------------------=
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2.4.3. Time
Once a dosage system has sufficient
coverage, time-pressured health-care
professionals need to be able to gen-
erate a dose from within this coverage
in a "reasonable" amount of time.
This is especially so given the afore-
mentioned and well-documented sen-
sitivity to this precious resource. As a
first approximation this capacity
should be measured over all doses.
Specifically, a Time measure can be
set to be the average time taken to
perform a dosage calculation over all
the possible dosage calculations that
make up the system's coverage. This
time consists of 4 parts: The time; (1)
to locate/construct the correct dosage
calculation (2) to input the relevant
parameter values (3) to perform the
mechanical evaluation and (4) to per-
form any final checks. Since compo-
nents (2), (3) and (4), depend on
factors that are essentially independ-
ent of whether a FCAD is a Selector
or Constructor, it is component (1)
that can be used to differentiate a
FCAD's efficiency and used as a first
approximation when evaluating
respective feasibilities.
2.4.4. Comparing 
Constructors & Selectors 
It is when considering the time
taken for a user to construct or locate
the relevant dosage calculation in
either a Constructor or a Selector that
a fundamental difference begins to
emerge. A Constructor, consisting of
a single interface, allows users to
focus on constructing a formula by
identifying those variables relevant to
the dosage calculation. Conversely,
users on a Selector, having performed
a similar variable identification, then
need to also find the correct interface
from amongst its existing repertoire.
It is precisely this additional selection
time, we argue, that has prevented
FCADs from becoming a viable alter-
native to current practices in the clini-
cal setting.
In the Drugulator embodiment of a
Constructor FCAD, it is estimated
that a proficient user should be able to
identify the relevant variables within
about 10 seconds. In a Selector
FCAD, users also have to identify the
relevant variables but then on top of
this, find the appropriate interface that
employs such variables in the correct
way. How long this takes will depend
on the number of interfaces in the
FCAD (and how well organized they
are). Even for a small number of vari-
ables however (e.g. those used to
define the Drugulator's coverage), we
argue that this time is significant for a
Selector containing a similar cover-
age. That is, we argue that a Selector
with a search of time of anywhere
between 30 to 40s can start to affect a
FCAD's practical usability given that
the total time also includes the afore-
mentioned parts (2), (3), (4) along
with the time for the physical admin-
istration. What is less arguable
however, is how these practical dif-
ferences become magnified once
additional variables are augmented in
the system (e.g. as part of an integra-
tion with a CPOEcds). More precisely;
as previously observed, the coverage
of Selectors, being equivalent to the
number of interfaces it contains,
increases exponentially in the number
of variables compared with a linear
increase associated with Constructors.
2.4.5. Correctness
Once a system has adequate Cover-
age and a feasible Time metric value,
the final component needed to evalu-
ate the system's effectiveness is how
often users generate the correct dos-
age. Again, as with the prior two met-
rics, this metric should be a measure
over all the doses within the system.
That is, a FCAD's Correctness meas-
ures the percentage of calculations
that users get correct over the FCAD's
coverage. One feature of Construc-
tors that enhances their Correctness is
that by effectively constructing the
appropriate formulae through interac-
tions with its interface, users need to
bring to bear their mathematical/lin-
guistic understandings in a similar
way as they would using pen/paper/
calculator. What this means is that
users interact with the system in those
areas that require human abilities -
namely in the translation from a drug
dose into a mathematical expression.
Compare this with the inherent pas-
sivity of selecting an appropriate dos-
age calculation from within a
Selector. This passivity contains two
inherent risks; the first involves
selecting a similar but incorrect inter-
face while the second arises in the
case of no appropriate interface being
available. In this latter case there is
the inevitable temptation to co-opt an
existing but inappropriate interface.
Finally, it is also worth noting the
potential increases in correctness
common to the automation inherent in
both Constructor and Selector
FCADs; namely the mechanical eval-
uation of a formula together with the
opportunity to cross-check with safe
dosage-ranges from digital pharma-
copoeias.
One feature, implemented in the
Drugulator, but not related to its con-
structor nature, is that any generated
dosage is always accompanied by the
mathematical expression used to gen-
erate it (The expression to the left of
the "=" sign in the interface). This can
be an indispensable aid for checking
since it confirms to the user, the
underlying algorithm being used by
the system. Given the lack of user-
input in constructing the correspond-
ing mathematical expression in exist-
ing Selectors, such a check would
presumably assume greater signifi-
cance in these systems although
somewhat curiously, such a feature
appears to be very seldom imple-
mented.
2.4.6. Summary
In this section we introduced an
Efficiency Index which, together with
other measures - Coverage, Time and
Correctness - can be used to evaluate
a FCAD's potential usability. We have
used these metrics in relation to the
Drugulator, a type of constructor
FCAD, and argued that using a selec-
tor-based FCAD quickly comes infea-
sible as additional factors are
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incorporated - as occurs with dosing
of increasing sophistication. The Dru-
gulator method can be thought of as
lying half-way between the extreme
of having complete freedom to com-
pute anything (pen/paper/calculator)
and the other extreme of only being
able to compute those dosages that
apriori have been added to the sys-
tem. The net effect of this "betwixt-
ness" is that a human's input is being
emphasized where it is most needed -
in constructing a formulae from a
clinical situation - whilst maintaining
the capacity to de-emphasise it where
it is least needed - in the formula's
mechanical evaluation.
3. Extensions/Relations
3.1. Constructor CPOE  
Systems
The previously developed metrics
aimed to evaluate FCADs as part of
the Administer stage in the process of
medical management. The main prin-
ciple underlying constructors can
however, also be applied to CPOEcdss
as part of the first Prescribe stage.
Indeed improvements in usability
provided by the constructor idiom,
are potentially more pronounced in a
CPOEcds system given that these
improvements are compounded each
time a new variable is added.
For example, even incorporating
one extra variable - Patient Weight - is
correlated with elevated levels of both
medication errors and ADE rates[14,
34] within paediatric dosing and
intensive care units. To be sure, this
correlation between weight-based
paediatric dosing and ADE rates does
not reflect a single causal link given
other risk factors such as narrower
"therapeutic windows" for young
children as well as a reduced capacity
to communicate adverse reactions.
Nonetheless, the complexity of a dose
is a significant factor in error rates
and in the case of patient weight this
has been indicated even for non-pae-
diatric situations[35, 36]. The poten-
tial effects on ADE rates therefore, is
potentially much greater when includ-
ing some or all of the following fac-
tors: Patient Weight, Age, Surface
Area, Renal Function, Liver Func-
tion, Drug-Allergy, Drug-Drug Inter-
action and even emerging DNA
individualization. Most of these fac-
tors have been identified as being
integral to a comprehensive CPOEcds
application [26, 37] and can also be
potentially applied in defining indi-
vidual biochemical profiles as part of
personalized dosing [38].
Clearly applying the constructor
principle to CPOE systems would
lead to adjustments in the underlying
algorithms depending on what addi-
tional variables are activated as part
of the calculated dosage - effectively
integrating a form of clinical decision
support. Whatever the adjustments,
our experience with the Drugulator,
suggests that any applied algorithm
be made as transparent as possible
(admittedly this is more straightfor-
ward in the Drugulator since it is an
arithmetical, proportional relation-
ships that are being communicated).
Users appreciated knowing exactly
how an answer was obtained since it
increased both their understanding of,
and their confidence in, the system.
While this would be more difficult to
implement in a CPOE (given that
decision rules effectively need to be
communicated) we argue that similar
levels of proficiency and confidence
would be inspired by a similar levels
of transparency. Such transparency
requires developing an appropriate
terminology [39] but ultimately ena-
bles a final human check or else a
confident override in the case of a
“false alarm” - a common problem
amongst existing CPOEcdss [26].
One feature of CPOEcdss that nicely
crystallizes the distinction between
Constructors and Selectors is the use
of so-called quick orders or their col-
lective counterpart, Order Sets (col-
lections of ordered quick orders). In a
quick order, input fields are pre-
defined and usually filled in with
(editable) default values so that their
application employs a process in
which physicians select a particular
order amongst a larger set of possible
dosages. Adding such a feature to
CPOEcdss has shown some promise
[19] [20] [40] mainly because imme-
diately selecting a dose can, in stand-
ard situations, be more efficient as
well as reducing the likelihood of
transcription or inadvertent errors.
Such an approach however, will
always be fundamentally limited by
the large number of quick orders that
must inevitably result from doses
formed by combinations of several
variables. That is, once the number of
order sets becomes sufficiently large,
the accompanying search problem
will inevitably and rapidly lead to a
general loss of efficiency. This was
noted earlier in this section and the
limitation has been readily observed
in the CPOEcds context [41] [42]
(where, for example,one CPOEcds sys-
tem contained 7423 quick orders
[41]).
Others have reported a great deal of
effort spent developing hundreds of
order sets only to later realize that
personal order sets were neither val-
ued nor often used (at only 13% of the
time [41]). In addition to the time
spent on the initial build of the order
sets, finding the correct one in the
system, and routine maintenance or
updates can quickly become over-
whelming [20].
There have been some approaches
to managing large numbers of order
sets by restricting the search to those
sets judged most applicable for any
given patient. Determining these
"most likely" order sets can be done,
for example, by using patient's admis-
sion diagnosis, ward location or clini-
cal service [20] and can also include a
probabilistic analysis of such factors
[40] or even the application of neural
networks [43]. The constructor
approach illustrated in the Drugulator
provides an alternative method of
efficiently navigating this large
"order-space". It allows physicians to
generate an order by first selecting the
order's relevant variables while
simultaneously requiring them to
apply their human judgment where it
is appropriately required.
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It is worth noting that the aforemen-
tioned advantages and accrued
knowledge associated with imple-
menting Order Sets in CPOEcds sys-
tems can still be usefully transferred
to a Constructor. For example, the
menu categorizations created for
Order Sets has a "Variable Sets" ana-
logue within Constructors (which
should also be made customizable in
the Drugulator as it is in CPOEcds sys-
tems [44]) while recurring default
values in the input fields of selected
variables would continue to act as
time-savers. While these would
improve the Drugulator and any other
Constructor, it is important that the
flexibility of being able to "activate" a
relevant variable and change its corre-
sponding input fields be maintained
lest the system slip back into becom-
ing a Selector.
The sheer complexity of the medi-
cal dosing pathway ensures that the
design of CPOEcds systems, assisting
even the first Prescribe stage, will
inevitably be of considerable com-
plexity and face ongoing challenges
[45] [46]. Indeed, as of 2007,
“designing a complex yet flexible,
protocol-based, safe dosing approach
to chemotherapy remains a relatively
unsolved problem in most institutions
implementing CDS within CPOE”
[19]. One important aspect of this
design includes physicians being able
to digitize orders in a timely manner.
The constructor principle imple-
mented in the Drugulator allows com-
puter-aided dosage calculation in the
Administer stage of this process
which, as we have just argued, can be
extended to provide similar efficien-
cies in a CPOEcds system focussing on
the Prescribe stage. In whatever way
the dosing problem is eventually
"solved", a degree of uniformity
between both FCAD and CPOEcds sys-
tems as a way of connecting more
closely the Prescribe and Administer
stages of the medication process,
would be beneficial.
3.2. Pharmodynamics & 
Pharmacokinetics
Advances in the detail and sophisti-
cation of mathematically modelling
in both pharmodynamics and pharma-
cokinetics come with the associated
computational problem of transfer-
ring such findings into practical clini-
cal orders that can be efficiently
generated by time-pressured health-
care professionals. The simplicity,
uniformity and extensibility of Con-
structors provide a technological
bridge across which more sophisti-
cated, and possibly more efficacious,
dosage regimes can be implemented.
That is, using a similar Constructor
system to collate and manage increas-
ing number of dosage factors as part
of pharmodynamic and pharmacoki-
netic research, potentially allows a
more seamless transition between
outcomes of this research and their
eventual clinical application. In par-
ticular, having the same apparatus for
both domains reduces the likelihood
of discovering efficacious new dos-
age regimes, which are nonetheless
too complex to be usefully and rou-
tinely applied in the clinical setting.
Conversely, this uniformity means
(suitably anonymised) usage data can
be fed back into this research pro-
gram, and more specifically, contrib-
ute to a standardization that has been
argued as being critical in uncovering
ADE origins [47] [48].
3.3. Competency and 
Pedagogy
The reader will have noted that of
the discussed measures Coverage,
Time, and Correctness, inherent in the
last two is a subjective evaluation of a
user's competence in driving any
tested FCAD. This competence is, in
turn, also related to the effectiveness
of any accompanying training pack-
ages which can also be used to estab-
lish benchmarks that more rigorously
establish a FCAD's effectiveness. In
relation to the Drugulator, its website
currently contains a user manual
although currently no inbuilt assess-
ment system yet exists to establish
such benchmarks. Naturally such
benchmarks can also help establish,
to a much higher degree than has pre-
viously been possible, the compe-
tency of health-care professionals in
the area of dosage calculations.
In this paper the Drugulator is being
put forward as representing a possible
paradigm shift in the way dosage cal-
culations are performed in the clinical
environment. Learning to operate the
Drugulator however, requires learn-
ing a principle that underpins all nurs-
ing calculations and hence can still be
of benefit to students learning dosage
calculations with traditional methods.
It is in this capacity that the Drugula-
tor is currently being used at Victoria
University and which we briefly
describe. 
Recall that the vast majority of dos-
age calculations expected of nurses
are based on the straightforward con-
cept of a dependent variable changing
in proportion to one or more other
independent variable(s). Unfortu-
nately, this concept is often obscured
by a variety of factors that make these
calculations more complicated than
they really need to be. Some of these
factors include: an over-reliance on
formulae in education; the need to
perform the arithmetic by hand or cal-
culator; the additional bookkeeping
imposed from multiple independent
variables along with any unit conver-
sions; and finally, the need to some-
times perform preliminary stock
concentration calculations. By apply-
ing the Drugulator and in particular
by automating many of these obscur-
ing factors, the conceptual essence of
the calculation crystallizes: the identi-
fication of the in-proportion relation-
ship between the relevant dependent
and independent variable(s).
3.4. Lessons Learned
As previously illustrated, the initial
Drugulator interface was imple-
mented within an internet web-
browser (also see Figure 12). As
development and trials proceeded
however, it became clear that inter-
face interaction was every bit as
important as the structure of output
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generated from the attached computa-
tional back-end. Web-browsers how-
ever, do not contain the same
flexibility and features of other envi-
ronments optimized for interface
development. Hence, while the result-
ing web-presence is clearly useful
from a dissemination viewpoint (ena-
bling users to, at least, get a feel for
the Drugulator's operation), a clinical
application would benefit from one of
these more powerful interface envi-
ronments.
In the Drugulator development,
while recognizing and implementing
an “all-purpose” mathematical algo-
rithm was an important starting point,
it quickly became apparent that a
wider range of expertise would be
necessary to capitalize on the oppor-
tunities arising from any introduced
automation. In particular, as part of
any possible systemic change it
became clear that any truly effective
FCAD, would require sustained input
from nurses, physicians, specialists in
medical informatics, information
technologists, graphic designers, edu-
cators, software engineers, usability
experts and designers of both digital
pharmacopoeias and CPOEcdss.
The importance of an integrated,
multi-disciplinary approach has often
been noted[6] [8] [46] but remains an
elusive goal mainly due to the high
upfront costs associated with the nec-
essary technological and cultural con-
vergence. In a later section, A
Developmental Blueprint, it is shown
how the Drugulator’s design (and that
of any Constructor) can address this
via an inbuilt extensibility that could
be further enhanced by the develop-
ment of more refined FCAD and
CPOE standards. From our experi-
ence with the Drugulator, the follow-
ing two factors represent the most
significant in relation to any potential
FCAD standards. Firstly, any internal
computations or algorithms should
always be made as transparent as pos-
sible to the user and secondly, that a
Constructor idiom be adopted as a
way of allowing users to construct a
patient’s dose.
3.5. Alternative 
Implementations
Thus far, the term The Drugulator
has been used somewhat interchange-
ably referring sometimes to the online
interface and sometimes to the web-
site. Most accurately however, it is a
method for performing dosage calcu-
lations characterized by the previ-
ously discussed constructor idiom.
The interface and technical infrastruc-
ture as described in this paper repre-
sent a first, working implementation
of this method - but others are possi-
ble and probably more desirable.
A discussion of the design princi-
ples underpinning of the Drugulator's
interface was deferred to emphasise
the primacy of first developing met-
rics to evaluating the performance of
any implemented dosage-calculator.
In line with this, some of the design
features introduced in the Drugulator
remain to be fully tested with the
objectivity of such metrics. There are
however, some central questions con-
cerning the optimality of particular
features that arise from the adoption
of Constructors - many of which are
currently being investigated. Such
questions about the Drugulator design
include but are not limited to: What is
the optimal arrangement of the
selectable variables? (static or
dynamic order, permanently visible or
accessible via a menu); How should
the Drugulator variables most easily
be selected? (using click order or via
a menu); How should the Stock Con-
centration interface be integrated with
the Drugulator? (permanently visible,
via a pop-up, with outputs automati-
cally inserted into Drugulator fields);
What is the most seamless method for
transferring Drug Order data into the
Drugulator interface? (simulating
Drug Chart templates etc); How
should the internal algorithms be
most clearly communicated to the
user? (variations in arithmetic form,
real-time updates, natural language
explanations).
 
An important decision affecting
clinical practice with the Drugulator
concerns access from either a stand-
ard computer screen or via a hand-
held device. The easiest path both
logistically and technically is via a
single computer screen (for example
an internet-connected workstation
can now access this Drugulator
implementation). In an initial pilot
study however, ready access to these
in-demand workstations became an
issue in the clinical setting so that
migration to an individual hand-held
device is most likely preferable. Such
a migration raises several questions:
what design changes are needed for a
smaller screen? Should the enabling
software reside on the hand-held
device or within a central location
accessed wirelessly? How can the
integrity and security of any wire-
lessly transmitted information be
guaranteed? Should the hand-held
device leverage current PDA technol-
ogies or become a custom-made med-
ical application? While these
questions represent significant design
and technical challenges, none appear
inherently intractable and are cur-
rently being investigated as part of the
Drugulator's development.
The current Drugulator implemen-
tation adopts a client-server architec-
ture in which a single web server is
being used to distribute dosage calcu-
lations to any number of clients
(Internet Explorer browsers). An
alternative architecture would be to
posit the application entirely on the
user's individual machine or handheld
device. Both types of architecture
have advantages/disadvantages
although there are particular clinical
imperatives that probably make the
client-server model more appropriate
for a comprehensive FCAD. One of
the main advantages of the client-
server model is that any upgrades to
the system's logic can occur centrally
and from the user’s perspective,
unobtrusively and without any mass
distribution of software upgrades. In a
FCAD such upgrades assume special
significance in relation to safety given
envisaged integration with large digi-
tized pharmacopoeias and/or more
complex dosage calculating algo-
rithms.
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The other opportunity offered by a
client-server architecture is the ability
to record all usage of the system by
health-care professionals. While this
inevitably raises privacy issues, once
these are judiciously managed, broad
opportunities exist for continuous
systemic improvement. For example,
the usage data can yield immediate
electronic trails for ADE audits and
evaluations of the systems perform-
ance in relation to the metrics dis-
cussed earlier. Finally, while a client-
server implementation in the clinical
situation would most likely posit the
server at the hospital level, the web-
based, client-server implementation
allows a ready dissemination of its
method as well as, educationally,
being a reasonably cost-effective way
of reaching large number of students.
3.6. Developmental 
Blueprint
The optimal, relative emphases of
human input verses automation in
health-care ultimately depends on
preserving those tasks that require
human judgment while developing
systems to manage the more mechan-
ical, repetitive tasks. In relation to the
medication process, the initial human
judgment required to compose a dose
is typically followed by a series of
steps, many of which are of an algo-
rithmic nature and therefore amenable
to advantageous automation. Cur-
rently, any automation within these
steps is implemented on a somewhat
ad-hoc basis and consists to varying
degrees of, for example: CPOEcdss;
hand-held calculators;  PDAs;  IV
Pumps and more recently, bar-coding
and robotic dispensing. The automa-
tion introduced by the Drugulator
involves the construction of a dos-
age's mathematical formulation in the
Administer stage. It also however,
creates a pathway for further incre-
mental automation associated with
each of the variables used in the for-
mulation. The following is an illustra-
tion of a possible endpoint for this
pathway in relation to a FCAD in the
Administer stage (compare with a
suggested automation across the
entire medication process [49]).
3.6.1. A Hypothetical 
Scenario
Nurse Betty is alerted by her Drug-
ulator beeping that Mary - one of her
patients - is now due for her next
dose. She then activates her Drugula-
tor's "medical records" module to
download any physician updates and/
or details relevant to Mary's base dose
(including adjustments due to her
body weight and dose schedule).
Betty checks the Drugulator screen to
confirm that indeed the correct values
have been imported into the inter-
face’s Patient Weight and Time bands.
She then activates the Drugulator's
"inventory module" to obtain the
location of the nearest drug cabinet
containing the required stock. After
arriving at the cabinet Betty then
attaches her Drugulator to the desig-
nated bottle and activates the Drugu-
lator's "scanning module" on the
bottle's barcode to confirm the correct
drug selection. She then looks at the
screen to ensure that the correct con-
centration values have been imported
into its Stock Concentration interface
(and in particular, its Drug Weight and
Drug Volume bands). Satisfied with
this, Betty then triggers her Drugula-
tor's "extraction module" to extract
the required drug amount before this
is automatically transferred to the
attached "delivery module" - in this
case a syringe. Betty then proceeds to
Mary's bedside before again activat-
ing the "scanning module" on Mary’s
barcoded wristband to confirm her
identity. She then checks the Drugula-
tor’s screen to confirm both the dose’s
mathematical expression and the rea-
sonableness of the evaluated answer,
before performing a more compre-
hensive final check by activating
(through a wireless connection) her
Drugulator's "drug pharmacopeia"
and "medical records" modules.
Finally, with all these checks passed,
Betty activates the drug-delivery
release module and administers the
injection upon which the relevant
modules wirelessly update Mary's
medical records and the hospital
inventory.
Such a scenario although hypotheti-
cal is also fairly natural to envisage
given the relevant technological
developments and indeed, in different
guises, has been the subject of numer-
ous patents [50] [51] [37] [50]
[53][54][55][43][56][57][38]. It is
also now being pursued as part of the
Drugulator’s commercialisation. Its
ultimate feasibility however, rests
crucially on the usability and extensi-
bility of any implemented interface –
both of which, we argue, are
addressed by a constructor model.
The usability advantages in terms of
reducing the time taken to calculate a
dose have already been discussed but
equally important is an inherent
extensibility to allow for future
changes in dosage regimes and differ-
ing rates of technological develop-
ment. In particular, the rationale
behind the Drugulator, or any Con-
structor, being the core interface
through which a pathway towards the
described automation can be
achieved, rests on its focus on a calcu-
lation's relevant variables. Each varia-
ble contributing to a final dose
represents an opening for human error
and therefore also an opportunity for
improving safety by the automatic
and human checking of such inputs. It
represents a pathway rather than an
instant solution because the automa-
tion can be progressively imple-
mented and not rely on a
technological confluence that
requires a simultaneous activation of
all the respective modules. For exam-
ple, a deployment in one setting may
have wireless connections to digitized
patient records but still require the
manual inputting of drug concentra-
tion data until such time as all its stor-
age bottles have been bar-coded. In
another health care system, in the
developing world for example, there
may be no opportunities to automate
any inputting so that all inputs need to
be manually added as described in
this paper.
4. Conclusion
Finally we collate and summarize
what we see as the key advantages
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and possible drawbacks of the Drugu-
lator system.
4.1. Advantages
Realising Automation: Automat-
ing any component of the medication
process offers the promise of greater
correctness, efficiency and ultimately
safety particularly for those compo-
nents that are sufficiently “mechani-
cal”. Drug calculations especially
their construction and evaluation,
clearly possesses this mechanical
nature and hence are amenable to
future automation. Any potential
automation however, is still condi-
tional on any implementation attain-
ing a high degree of usability. This is
because at some point in the medica-
tion process, human judgement is still
required in any system interaction.
The rationale behind the Drugulator
method is that, in the face of a diverse
and possibly increasing range of pos-
sible drug calculations, the type of
human interaction facilitated by its
single interface can, and perhaps
uniquely so, allow this level of usabil-
ity to be reached.
Progressive Improvement: There
exists a clear entry barrier related to
the level of development required
prior to clinical application and this is
identified as such in the next Disad-
vantages section. With this barrier
surmounted however, the Drugulator
method is also “future proof” in two
important senses. Firstly it can be
progressively connected to other
medical systems while secondly; its
claimed usability is not compromised
by an inevitable increase in drug-cal-
culating sophistication and precision.
4.2. Disadvantages
Quantum of Change: One factor
militating against an eventual adop-
tion of the Drugulator method is that
it is, in some ways, a radical departure
from current methods. Consequently,
there is a large quantum of develop-
ment, implementation and attitudinal
change required to overcome long-
standing and entrenched practice.
Reaching such a point may not be
achievable organically in small incre-
mental steps but instead, require a
large injection of resources and insti-
tutional commitment typically predi-
cated on widespread, expensive trials.
Steepness of Learning Curve: The
Drugulator, like any tool, requires a
period of familiarization and training
before its efficiency and accuracy
gains start to become realised. In this
initial implementation, a training
period of a few hours was sufficient
before most learners reached compe-
tence. This however, was based on
instruction been provided by the
developers and hence could possibly
be greater within an uninitiated envi-
ronment.
Risks from Incorrect Input: The
Drugulator, like any automated proc-
ess requires, at the some point in the
medication process, correct input to
obtain correct output. While, as dis-
cussed, this is potentially mitigated
through automated checks with con-
nected systems, there remains the risk
of users driving the system without
applying their mathematical sense
either during its operation or in a final
check.
Premature Dependence: When
used as a pedagogical tool, the
Drugulator removes the need for the
manipulation and evaluation of any
constructed formulae. Prior to any
potential introduction into the clinical
environment therefore, care needs to
be taken to ensure that in any
training, it is only used after, or in
conjunction with, existing methods
(to this end, in the training of nurses
at VU, it is only used as an extension
to the standard to pen/paper/
calculator methods).
4.3. Concluding Remarks
This paper has introduced The Dru-
gulator - a new method for perform-
ing drug calculations. The method
can be used to underpin a computer
system through which it is envisioned
that health-care professionals can pro-
duce correct dosages with greater reli-
ability and efficiency. An initial, web-
based implementation of this method
is presented and illustrated together
with numerous examples. The Drugu-
lator method itself, points to a certain
constructor idiom having inherent
advantages over a selector idiom that
is currently being used in existing
systems. Indeed we have argued that
this new idiom not only makes cur-
rent point-of-care calculations feasi-
ble, but that it becomes indispensable
for any serious automation of more
sophisticated dosage regimes. This
would occur, for example in CPOEcdss
using increasing numbers of varia-
bles. Further, once such an idiom is
adopted we have suggested how,
through a progressive integration with
existing hospital systems, it can be
used as a pathway towards greater
automation and reliability in drug cal-
culation and delivery. 
Whilst the online Drugulator model
of this paper represents a working
implementation, we have also urged
that further testing be performed to
evaluate not only the Drugulator's
general performance but also any
FCAD being put forward as an auto-
mated dosage calculating system in
the Administer stage of medical man-
agement. Towards this end we have
defined several metrics and shown
how they can be used to capture a
FCAD's overall performance. While
the upfront cost of this putative test-
ing and development of a pathway to
increased automation in integrated
FCAD and CPOEcdss is obviously
high; it would also seem to be signifi-
cantly less than the enormous costs
associated with the damage currently
being inflicted through existing rates
of ADEs.
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5. Appendix
In this appendix we describe the
operation of the Drugulator interface
and how inputs are used to construct
a mathematical expression that is
evaluated on submission to the
computational back-end. By way of
several examples we then show how
this operation implements a unifying
principle that allows a wide array of
dosage calculations to be similarly
automated. Finally, a description of
the technical infrastructure and
accompanying website is described.
5.1. Forming the 
Mathematical Expression
We first show the mechanics of
how values input into the
Drugulator's input fields are
combined into an arithmetical
expression before later showing how
this expression corresponds to the
desired dosage. This forming of the
appropriate mathematical expression
corresponds to the "Formulaic-Aided
Dosing" used as part of our original
FCAD definition. In Figure 4, the
(red or orange) activated rows
contain inputs that are used to
generate a quotient that is used in the
dosage calculation.
If a row is activated as red then the
quotient is formed by taking the
L.H.S. value of the row (in the Dose
Ordered Column) and dividing by the
R.H.S. value of the row (in the Dose
Delivered Column). In the example
of Figure 4, the quotient so generated
is . Conversely, if a row is
activated as orange, then the quotient
formed reverses the roles of
denominator and numerator. That is,
the quotient is formed by taking the
R.H.S. value (appearing in the Dose
Delivered Column) and dividing by
the L.H.S. value (appearing in the
Dose Ordered Column). From Figure
4 the quotients so generated are 
and .
                                     Figure 4: Demonstrating how the interface’s various fields automatically 
                                        define a mathematical expression that is to correspond to a correct drug dosage.
All the quotients so formed from
the activated rows are then multiplied
together to form a product (as shown
on the left of the "=" button). This
product is then evaluated to a
numerical answer and placed to the
right of the "=" button once it is
clicked. This evaluated answer is
typically the amount of the dose to be
administered. Apart from some usage
details to be described later (relating
to the management of units and
activation of rows), this essentially
describes the mechanics of this
implementation of the Drugulator
method.
5.2. Implementing 
Proportional Relationships
As will be demonstrated, these
mechanics implement proportional
relationships that typically exist
between the final dosage and those
other factors that affect its final value.
Mathematically, these are
1A
1B------
3B
3A------
4B
4A------
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proportional relationship involving a
single dependent variable and other
independent variables. In the
Drugulator method, individual
variables are assigned fixed rows in
the interface and their dependent/
independent status is then activated
by clicking their corresponding
middle buttons within the Relevant
Variables column. The resulting
status is then indicated by each rows'
background colour under the
following identification: Dependent
↔ Red; Independent ↔ Orange;
Inert ↔ Blue1.
Hence we see that in the example of
Figure 4, Var 1 has been selected to be
the dependent variable while Var 3
and Var 4 have been selected as the
independent variables. Var 2 has been
left inert and therefore plays no part
in this particular calculation. Having
identified the dependent variable
(typically the dose amount) and the
independent variables (those varia-
bles affecting the dependent variable)
it remains to mathematically illustrate
the relationship between these two
types of variables. As mentioned pre-
viously, it turns out that for the vast
majority of dosage calculations
required at the administration stage,
the independent variables affect the
dosage (dependent) variable propor-
tionally. That is, changing an inde-
pendent variable by a certain factor
means that the base dose also needs to
change by this same factor. This sim-
ple principle, underpins a surprisingly
wide array2 of dosage calculations
and the way in which the interface's
mechanics implements this principle
can be observed as follows:
Dependent Variable:In the arith-
metical expression of Figure 4, the
factor contributed by the red row
(dependent variable Var 1) is . 
The term 1A can be interpreted as
the base dose with 1B the units
(sometimes defined per tablet) in
which this base is to be delivered. The
quotient  therefore effectively
ensures the final dosage amount is in
the correct units.
Independent Variables: It is
through changes in the independent
variable(s) that their proportionate
relationship to the dependent variable
is implemented. These changes are
from the values specified in the Dose
Ordered column to those value
specified in the Dose Delivered
column so that the factor change is
simply the latter divided by the
former. This can be seen
algebraically from the contribution of
the orange rows in Figure 4.
Ans =  with
, .
Since  the term 
represents the factor by which 
changes in becoming .
Equivalently,  represents the
factor by which the row's
corresponding independent variable
has changed from its value used in
the base dose. Therefore, due to the
assumed proportional relationship
between the dependent and
independent variable(s), the final
delivered dose needs to also change
by a factor of . That is, the
delivered dose - ( ) - needs to be
adjusted by multiplying it by this
factor . A similar argument
applies for  (and indeed any
number of other independent
variables should they be subsequently
defined) with the collective effect of
these factor changes being captured
in the final product - 
This completes the initial description
of the Drugulator's essential action
save for one minor point regarding
the specification of units. In Figure 4
the selected fields  all contained the
same values. This simplified the
description of the mechanics behind
the interface's formulae construction
but clearly in practice the possibility
of variable unit specifications needs
to be incorporated. In these cases the
terms , ,  are suitably
modified (with conversion factors
between different selected units) as is
described later in the section
Specifying Units. Before describing
some of the other features we give
three basic examples.
Example 1
A dose is to be calculated using the
following information which appears
in the Dose Description panel of the
interface as shown in Figure 5.
Chlorpromazine 400 mg oral is
ordered daily in 4 doses. Ward stock
is 100 mg/tablet. How many tablets
should be given in each dose?
1. Note that the dependent variable also has a non-color identification via a small white cross appearing in the top right-hand corner.
2. Surprising in the sense that traditional nursing education usually develops individual formulae for each dosage calculation thereby obscuring this 
single proportionality principle.
1A
1B------
1A
1B------
1A
1B------ 3F( )× 4F( )×
3F( ) 3B3A------= 4F( )
4B
4A------=
3A 3F× 3B= 3F
3A
3B
3F
3F
1A
1B------
3F
4F
1A
1B------ 3F( )× 4F×
1A 1B 1C
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                                          Figure 5: A simple example involving a Tablet Calculation
The question requests a number of
tablets which corresponds to a Drug
Weight - hence this is the main
dependent variable as reflected by
this row's red colour in Figure 5. The
amount of this Drug Weight in any
single dose depends on the frequency
of administration; that is, it depends
on the independent Time variable as
reflected in that row's orange colour.
The base dose is 400 mg per (1) day
as entered in the Dose Ordered panel.
This base dose needs to be varied
firstly in relation to the Drug Weight
where 100 mg units are effectively
being defined given that this is the
mass of each tablet. The base dose is
being delivered in 4 doses which over
1 day equates to a dose every 6 hours.
These variations are both specified in
the Dose Delivered panel. Finally,
note that the generated answer (of 1
tablet) includes the units with which
it is to be administered (i.e. with
100mg units and every 6 hours).
Example 2
Order: CL 2 gm in 5 % Dextrose 50
ml IV over 2 hours. DropRateFactor:
60
How many drops per minute are to
be infused?
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                                     Figure 6: Showing how dosage calculation involving a Drop Rate Factor  
                                        can be implemented in the Drugulator’s interface.
This example (transcribed into the
interface as shown in Figure 6)
involves a standard “DropRateFactor”
calculation usually performed using a
learned formula. This formula however,
also embodies a proportionate
relationship between dose and
independent variables and hence can
be calculated within the structure of
the Drugulator interface.
The request "how many drops per
minute" indicates that a Drug Volume
(in drops) is the sought-after
dependent variable with the number
of drops depending on the time over
which the drops are administered;
that is, with the amount depending on
the independent Time variable. This
is reflected in the Drug Volume and
Time variables being specified as the
respective independent (red) and
dependent (orange) variables.
The base dose of 50 ml/2 hrs is then
entered in the respective positions of
the Dose Ordered panel. This base
dose is being varied only in the units
in which it is to be delivered. The
standard terminology of a "Drop Rate
Factor" of 60 indicates that the dose
is to be delivered in drops of volume
 ml each. This is reflected in the
Drop (60) setting in the Dose
Delivered Panel with the Drop (60)
term therefore representing a volume
unit of  ml1. Finally, the time unit
is to be changed to minutes as entered
in the Dose Delivered Panel. Again
note that the final answer of 25 is
followed by the units to which the
base dose has been changed.
Example 3
The following example was first
described in the System Description
section and its solution in the
Drugulator interface is repeated
below in Figure 7. 
A child weighing 18.5 kg is
prescribed Benzyl Penicillin (IV) 40
mg/kg/day 6 hourly. How much
should be given in a single dose? 
1.  Note that placing 1/60 in the input field and choosing ml as the units would also yield the correct answer.
1
60-----
1
60-----
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                                        Figure 7: Showing a paediatric weight-based dosage calculation.
Based on the previous discussion,
the identification of Drug Weight as
the dependent variable and Time and
Patient Weight as the independent
variables follows naturally from the
description while the proportional
relationship between them, as before,
ensures that the constructed
mathematical expression corresponds
to the required dose. Note that
although not explicitly stated, it is
assumed that the Drug Weight is to
be delivered in the same units as that
provided in the dose (mg) and that, as
in the previous two examples, the
final independent units follow the
calculated answer of 185 mg.
5.3. Specifying Dependent/
Independent Variables
One of the reasons behind the Dru-
gulator's flexibility (and indeed of all
so-called Constructors as defined in
the Discussion section) is that for dif-
ferent scenarios, different variables
can be identified as dependent, inde-
pendent or inert. In the Drugulator
interface, each row is identified with
a variable via a button label contained
in the middle Relevant Variables
panel. A variable is then identified as
being dependent/independent (or
irrelevant) depending on whether or
not its button label was the first one
clicked. That is; the first variable but-
ton label clicked identifies its variable
as the dependent variable while sub-
sequent clicks on any of the remain-
ing button labels identify the
corresponding variables as independ-
ent. As mentioned earlier, these iden-
tifications are reflected in a colour
change of each variable's associated
row with red as dependent and orange
as independent.
So, for example, the identification
of Figure 7 can be made by simply
clicking the buttons in the following
order - Drug Weight, Time, Patient
Weight. (N.B. the order Drug Weight,
Patient Weight, Time also makes the
same identification). Note that
removing a variable's identification is
performed by clicking again on its
button label and is indicated by
having the variable's row return to its
"inert" blue colour1. Note also that
this variable identification is a
necessary first step since activating a
variable's row makes its row's inputs
editable (and is indicated by the
"undimming" of these corresponding
inputs).
It is easy to see that the
aforementioned algorithm for
selecting dependent/independent
variables always produces exactly
one dependent variable and (from the
remaining variables) between 0-3
independent variables. There are
constraints however, associated with
dosage calculations that make certain
configurations more likely than
others. For example, given that a
drug's weight or volume is most often
the primary quantity of interest; the
dependent variable is typically either
Drug Weight or Drug Volume. Note
also the inbuilt extensibility whereby
other variables can potentially be
defined using additional rows and/or
other relationships other than the
current proportional one between
dependent and independent variables.
This was discussed earlier in
1. If a dependent variable is rendered inert then the next inert variable label clicked identifies it as the new dependent variable. If an independent 
variable is rendered inert then subsequent variable clicks identify the respective variables as the new, independent variables.
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describing the relevance of a
Constructor’s  idiom to  CPOE
systems.
5.3.1. Specifying Units
Converting between different units
is not really part of the conceptual
understanding involved in calculating
standard drug dosages but is instead,
merely a reflection of the disparity
between the drug packaging and drug
prescription quantities. Fortunately,
in the Drugulator this task no longer
interferes with a dose's mathematical
conception since all conversions are
handled automatically. Recall from
Figure 4 how all the input values of
, ,  ... etc are measured in
the same units - namely Units (u).
Making such an assumption allowed
the essence of a dose's construction
from the interface's input fields to be
more clearly observed. Given that
each row is identified with a
particular variable however, the
actual range of units selectable in that
row will clearly depend on the units
with which that variable is typically
measured. So for example, the units
in the Drug Weight1 row contains a
drop-down menu consisting of
"micrograms (mcg)"2, "milligrams
(mg)", "grams (g)", "kilograms (kg)"
which covers the range of units
needed to describe this variable3. The
variable Patient Weight, on the hand,
only contains the units "grams" and
"kilograms" since these are invariably
sufficient to describe a person's body
weight.
When different units are specified
in any one row, a conversion factor is
required, effectively to ensure that
both the denominator and numerator
are being measured using the same
scale in the corresponding quotient.
This factor effectively converts the
units defined in the Dose Ordered
column into those units defined in the
Dose Delivered column. When the
variable is the dependent variable,
this factor appears as the numerator
(because of the way the quotient is
formed): when the variable is an
independent variable the factor
appears on the denominator (again
because of the reciprocal quotient).
For example, in the calculation of Fig
4, Drug Volume is the dependent
variable with respective units, "ml"
and "Drop 60". As changing from ml
to Drop 60 units (  th of a ml)
involves a factor of 60, this appears
on the numerator. Time is the
independent variable in this example
with respective units, hours and
minutes. As changing from hours to
minutes involves a factor of 60, this
factor appears on the denominator.
Any answer generated by the
Drugulator is always followed by unit
abbreviations corresponding to the
unit specifications of the independent
variables in the Dose Delivered
panel. These can be viewed as a
reminder of the new values taken by
those independent variables that
affect the patient's calculated dose.
Following normal convention, The
Drugulator separates these abbre-
viations with the symbol "/" (read as
"per") as well as dropping any unity
specifications. For example, 8 mcg/
min/kg conventionally denotes: "8
micrograms per "1" minute and per
"1" kilogram" (although note that the
omitted 1's still needs to be included
in the Drug Delivered panel).
Less conventionally, but we argue
more logically and safely, The
Drugulator never omits or alters any
abbreviated units that have been used
in the calculation. In particular, it
always includes the relevant units
specified in the Drug Delivered
panel. Conventionally these values
are sometimes omitted being assumed
from the context although we believe
this is a potential ambiguity that can
lead to unnecessary confusion about
what independent variables have been
incorporated. Hence, in the three
previous examples, the respective
answers of: 1 Tablet, 25 Drops and
185mg are traditionally sufficient
whereas the respective Drugulator
outputs of: 1 100mg/6hr, 25 Drop
(60)/min and 185 mg/6 hr/18.5 kg
reinforces that: 1 100mg tablet needs
to be administered every 6 hours; that
25 1/60 ml drops need to be infused
every minute and finally, that the 185
mg dose needs to occur for a 18.5 kg
patient every 6 hours.
5.3.2. Stock Concentration 
Interface
Drugs are often stored as mixtures
from which drug weight or drug
volume amounts are measured out
depending on the prescription type.
Furthermore, within the mixture, the
drug weight and drug volume are
proportionally related in a way
usually defined as the mixture's
concentration. But both Drug Weight
and Drug Volume are variables of the
Drugulator's interface which recall,
also implements proportional
relationships; hence it is ready made
to perform any preliminary
concentration calculations. Such
usage also dovetails nicely with the
Drugulator's idiom of reducing the
number of possible inputs by re-using
arguments. On the other hand,
outputs from stock concentration
calculations are invariably "plugged
1. Strictly speaking these are units of Mass so that it would actually be more accurate to name the variable Drug Mass instead of Drug Weight (which is 
a Force). The latter has been chosen to follow standard clinical terminology in Australia.
2. Note that strictly speaking, the SI abbreviation for "microgram: is " µ" but to avoid potential confusion with "g" it is standard to instead use "mcg"
3.  In principle making the unit specifications "inputable" (as opposed to the current "selectable") would extend the range of possible units. This may be 
useful if one would one to use some other SI abbreviation (pico, nano, etc) or other unit systems (e.g. Imperial) although it would also probably 
unnecessarily complicate the interface for the majority of calculations. (Future versions may at least provide this as an option).
1A 1B 1C
1
60-----
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into" the Drugulator interface
meaning that it would then need to be
activated twice for any dosage
requiring a preliminary concentration
calculation. This was a source of
some confusion (perhaps also
because this repeated usage renders
the panels headings with a double
meaning) in an early piloted version
so it was decided to create a separate
interface dedicated to these
preliminary stock-concentration
calculations. This additional interface
adds clarity in terms of sequencing
the concentration calculations while
the complexity introduced by adding
new inputs is minimized given that
the same idiom of dependent/
independent variables transfers from
the original interface. We now
illustrate a stock-concentration
calculation.
Example 4
The following example amounts to
finding an equivalent drug volume of
a drug weight based on a given stock
concentration (see Figure 8).
Andrea is ordered Penicillin V
250mg
Stock strength is 1g/10ml
Calculate the amount to be given.
 
                                     Figure 8: Showing how a preliminary Stock Concentration calculation 
                                        can be performed in the Drugulator’s L.H.S. sub-interface.
Note that while this particular
calculation can be straightforwardly
performed by inspection, more
cumbersome values (and unit
conversions) can still render such an
interface a useful calculating tool.
The real point however, is such a
calculation also embodies a
proportional relationship between
relevant variables and hence also can
be performed within the Drugulator
interface. In particular, this push for
uniform automation within a single
interface (to obtain all the potential
advantages previously discussed) can
be extended to include stock-
concentration calculations. Next we
clarify the nature of this extension
when applied to these stock-
concentration calculations.
 
Recall that a dependent variable -
the red row- is being identified as the
main quantity of interest and is set to
depend in proportion to an
independent variable in the orange
row. As can be seen in Figure 8 this
in proportion dependence is set up in
stock concentration calculations in
the same way as described earlier for
the R.H.S. interface. That is, if the
row is red the quotient formed is the
L.H.S. value divided by the R.H.S.
value (  in Figure 8): if the row is
orange, the quotient formed is the
R.H.S. value divided by the L.H.S.
value ( ). As before, unit changes
across any row are accounted for
using an appropriate conversion
factor ( ). Finally, note that the
generated output continues to include
the final independent variable amount
(250 mg). 
There are two modifications
specific to this stock-concentration
interface. Firstly, since in any stock
concentration calculation, it is always
the case that there must exist exactly
one dependent variable and one
independent variable (i.e. exactly one
red row and one orange row) any
initial click defining the
corresponding row as the dependent
10
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variable (thereby making it red)
automatically causes the other
variable to become independent
(thereby making it orange). For
example, the dependent/independent
identification of Figure 8 arises from
the single click of the Drug Volume
button  label.1
                                      Figure 9: The Drugulator Interface before starting a Drug Calculation.
The other modification in this inter-
face involves the re-labelling of the
left-hand side (L.H.S.) and right-hand
side (R.H.S.) panels to respectively
Stock Concentration and Dose Ordered.
The rationale behind such labelling is
that mathematically, the L.H.S. holds
the base values of any selected varia-
bles whereas the R.H.S. represents
how these values are changed. That
is, the Stock Concentration's panel
contains Drug Weight and Drug Vol-
ume values which represent a base
setting to be altered according to the
Dose Ordered amount. Note the same
Dose Ordered labelling of the inner,
adjacent panels of both interfaces.
This reflects the sequence whereby
any Drug Volume (Drug Weight)
value generated by the stock concen-
tration interface is typically
"plugged" back into Drug Volume
(Drug Weight) input fields of the
R.H.S. interface in the Dose Ordered
panel2. An example of this sequence
is contained in the next example.
A Bi-interface Example.
The final example shows the two
interfaces working together and
represents the more sophisticated
type of calculation possible in the
Drugulator system. Recall the initial
(inert) Drugulator interface showing
the left-hand “concentration
calculating” interface adjacent to the
right-hand side “dosage calculating”
interface (Figure 9).
Example 5
Order: Dopamine infusion 5 mcg/
kg/min for a 90 kg patient.
Stock: Dopamine 50 mg in 5%
Dextrose 1000 ml
How many ml/hr are to be infused?
First a preliminary calculation is
required to find a volume equivalent
to 5 mcg using the given stock con-
centration. This calculation is per-
formed in the L.H.S. interface as
depicted in Figure 10.
1.  This is the most common situation but the other alternative where a Drug Weight is required based on a quoted Drug Volume (e.g. when checking 
the output of any previous stock concentration calculation) can also be performed with a single click of the Drug Weight button.
2.  It is natural to want to automate this "plugging in" process. The “connecting valve” between the two interfaces (shown as “<>”) has been earmarked 
to perform and indicate such an extension.
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                                    Figure 10: Showing the preliminary stock concentration calculation in a 
                                       more involved example.
This stock concentration calcula-
tion shows that using the supplied
stock, 5 mcg is equivalent to 0.1 ml
and hence a dose of 5 mcg/kg/min is
equivalent to 0.1 ml/kg/min as
entered in the Dose Ordered panel of
the R.H.S. interface as shown in Fig-
ure 11. 
The variation on this base dose for
this particular administration involves
a 90 kg patient and a dose frequency
per hour as specified in the Dose
Delivered panel of Figure 11.  Finally,
on clicking the equal sign the final
dose of 540 ml/hr/90kg is generated.
Even in this more involved exam-
ple, the calculation’s individual steps
are still mathematically trivial given
that they all ultimately reduce to frac-
tion multiplication. When contextual-
ized within the demands of a clinical
situation however, the necessity for
such computer-aided assistance
becomes more apparent (apart from
persistently high ADE rates). For
example, consider the accompanying
tasks required of health-care workers:
they need to; apply natural language
interpretations to form the correct
fraction, evaluate the fraction either
by hand or calculator (while remain-
ing alert to the possibilities of
required unit conversions), perform
any final checks, deal with the physi-
cality of dose measures and adminis-
tration all under considerable time
pressure. Further, these demands
become compounded with increases
in the complexity of dosage regimes
(that incorporate, for example, addi-
tional variables) to the point that, we
argue point-of-care calculation
becomes infeasible without this type
of FCAD assistance. The structure
provided by the Drugulator provides a
consistent framework in which the
natural language interpretation, math-
ematical evaluation and final checks
can be automated.
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                                     Figure 11: Showing the second step (after the initial Stock Concentration
                                        calculation) in a more involved example.
5.3.3. Technical 
Infrastructure
This particular implementation of
the Drugulator is accessed from a
website and therefore adopts predom-
inantly a client-server model as
shown in Figure 12. An Apache web
server initially handles general
requests from the Drugulator website
before passing Drugulator-specific
inputs on to a Tomcat server. This
server, in turn, transfers the inputs to
Mathematica (via a webMathematica
application) which then calls a Drug-
ulator package that evaluates the
mathematical expression. Hence, in
this model, the mathematical expres-
sion is first constructed within the cli-
ent (using Javascript within an
Internet Explorer Browser) before
being sent to a computational back-
end (a Mathematica kernel) for evalu-
ation. The development environment
used to develop the web webMathe-
matica, Javascript and Mathematica
code (of the Drugulator package) was
the Wolfram Workbench with version
control provided by the Subversion
plug-in.
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     Figure 12: The architecture of first Drugulator implementation connecting a (Javascript-enabled) web-browser 
        with a (Mathematica)  computational backend.
